Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
Ligand to Hold Investor and Analyst Day on December 13
Ligand Reports Third Quarter 2022 Financial Results
Ligand Announces Completion of OmniAb Spin-Off
Ligand Distribution of OmniAb Complete and Business Combination Closed
Ligand to Report Third Quarter Financial Results on November 7
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
OmniAb Business Combination Approved by APAC Shareholders
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Ligand Reports Second Quarter 2022 Financial Results
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Ligand to Report Second Quarter Financial Results on August 8
